Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01190865 · ClinicalTrials.gov registry record · Phase 1
Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds
A Phase 1 study, sponsored by Healthpoint.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01190865: Completed Phase 1 study, sponsored by Healthpoint.
NCT01190865 is a Phase 1 study that has completed, run by Healthpoint. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01190865, a Phase 1 study, has completed, sponsored by Healthpoint.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The goal for this study is to examine the persistence of growth arrested,allogeneic,male-donor keratinocytes and fibroblasts when applied as product HP802-247 to the surface of acute excisional wounds in health female volunteers, as measured using Y-STR for detection of Y-chromosome.
Primary Outcome
The primary efficacy variable was detection of the full set of 17 Y STR loci. If all loci amplified such that a clear identification of a donor was possible, the test result was categorized as positive. If fewer loci amplified such that identification of the donor was not possible in a forensic setting, the result was categorized as negative. Descriptive statistics are presented for this variable.
Interventions
- BIOLOGICAL HP802-247
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-09 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
What the finished NCT01190865 record still lists
NCT01190865 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 1 intervention - of which HP802-247 is the first listed.
NCT01190865 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01190865 about?
NCT01190865 is a clinical study titled "Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds". The goal for this study is to examine the persistence of growth arrested,allogeneic,male-donor keratinocytes and fibroblasts when applied as product HP802-247 to the surface of acute excisional wounds in health female volunteers, as measured using Y-STR for detection of Y-chromosome.
What is the current status of trial NCT01190865?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2010-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01190865?
The interventions under investigation include: HP802-247 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01190865?
This trial is sponsored by Healthpoint, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01190865's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia